Jun 26, 2026 04:02PM
Jun 26, 2026 03:59PM
May 26, 2026 10:46AM
Oct 19, 2025 03:59PM
Jun 27, 2025 07:37PM
Nov 7, 2024 06:59AM
Oct 30, 2024 03:24AM New data for emapalumab in the treatment of macrophage activation syndrome to be presented at the ACR conference
Jul 16, 2024 05:17AM
Jul 2, 2024 02:23AM
Jun 19, 2024 02:17AM
May 24, 2024 03:16PM
Apr 26, 2024 08:02AM
Nov 20, 2023 02:36AM
Jul 18, 2023 04:39AM Sobi publishes Q2 2023 report: Growth and pipeline expansion
Jun 26, 2023 09:45AM
Jun 25, 2023 11:18AM
Jun 24, 2023 06:49AM
May 30, 2023 04:35PM
May 19, 2023 01:58AM
May 10, 2023 01:32AM
Apr 4, 2023 07:00AM Annals of Rheumatic Diseases Publishes Results from Phase 2 Study of emapalumab in Patients with Secondary HLH/Macrophage Activation Syndrome
Mar 21, 2023 03:51AM
Nov 11, 2022 05:04AM
Nov 10, 2022 07:00AM
Oct 27, 2022 06:59AM
Jul 8, 2022 02:59AM
Jul 8, 2022 02:00AM
Mar 9, 2022 01:14AM Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in haemophilia A, demonstrating superiority to prior factor prophylaxis treatment
Nov 4, 2021 10:45AM
Sep 7, 2021 08:00AM
Jul 7, 2021 02:11AM
Jun 1, 2021 02:39AM
May 25, 2021 07:54AM
Mar 17, 2021 05:48PM
Mar 12, 2021 03:12AM First patient dosed in phase 3 study with avatrombopag for treatment of ITP in children
Jan 20, 2021 02:58AM
Dec 22, 2020 10:36AM
Dec 11, 2020 07:09AM
Dec 10, 2020 06:18AM
Dec 10, 2020 06:10AM
Dec 10, 2020 06:00AM
Dec 10, 2020 03:54AM Emapalumab submission in China for primary HLH
Nov 19, 2020 06:58AM
Nov 19, 2020 06:45AM
Nov 6, 2020 09:17AM
Nov 4, 2020 02:54AM
Oct 9, 2020 07:36AM
Sep 30, 2020 05:43PM
Sep 30, 2020 04:15PM Selecta Biosciences and Sobi Announce Topline Data of SEL-212 from the Phase 2 COMPARE Trial Supporting the Potential for Important Clinical Improvement in Patients with Chronic Refractory Gout
Sep 23, 2020 07:14AM

324,655 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All